AllianceBernstein’s Alexion Pharmaceuticals ALXN Stock Holding History

AllianceBernstein’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,254,045	Closed	-$230M	–	3415
2021 Q2	$230M	Sell	1,254,045 -218,732	-15%	-$37.5M	0.09%	211
2021 Q1	$225M	Buy	1,472,777 +37,168	+3%	+$5.75M	0.1%	204
2020 Q4	$224M	Sell	1,435,609 -68,180	-5%	-$8.76M	0.11%	176
2020 Q3	$172M	Buy	1,503,789 +89,541	+6%	+$9.66M	0.09%	189
2020 Q2	$159M	Buy	1,414,248 +208,696	+17%	+$22.2M	0.09%	193
2020 Q1	$108M	Sell	1,205,552 -34,484	-3%	-$3.38M	0.08%	236
2019 Q4	$134M	Buy	1,240,036 +116,386	+10%	+$12.4M	0.08%	244
2019 Q3	$110M	Buy	1,123,650 +642,169	+133%	+$72.4M	0.07%	283
2019 Q2	$63.1M	Buy	481,481 +21,164	+5%	+$2.73M	0.04%	472
2019 Q1	$62.2M	Sell	460,317 -16,469	-3%	-$2.05M	0.04%	456
2018 Q4	$46.4M	Sell	476,786 -8,152	-2%	-$964K	0.03%	499
2018 Q3	$67.4M	Buy	484,938 +29,369	+6%	+$3.68M	0.04%	423
2018 Q2	$56.6M	Sell	455,569 -121,409	-21%	-$14.2M	0.04%	463
2018 Q1	$64.3M	Sell	576,978 -28,489	-5%	-$3.41M	0.05%	419
2017 Q4	$72.4M	Buy	605,467 +89,875	+17%	+$10.9M	0.05%	398
2017 Q3	$72.3M	Sell	515,592 -49,522	-9%	-$6.73M	0.05%	386
2017 Q2	$68.8M	Sell	565,114 -1,843,575	-77%	-$215M	0.05%	388
2017 Q1	$292M	Sell	2,408,689 -453,839	-16%	-$58.5M	0.23%	98
2016 Q4	$350M	Sell	2,862,528 -31,892	-1%	-$3.9M	0.29%	79
2016 Q3	$355M	Buy	2,894,420 +424,660	+17%	+$54.7M	0.3%	80
2016 Q2	$288M	Buy	2,469,760 +336,527	+16%	+$47.7M	0.25%	93
2016 Q1	$297M	Buy	2,133,233 +936,763	+78%	+$138M	0.25%	97
2015 Q4	$228M	Buy	1,196,470 +641,294	+116%	+$112M	0.19%	117
2015 Q3	$86.8M	Buy	555,176 +50,384	+10%	+$9.19M	0.07%	275
2015 Q2	$91.3M	Buy	504,792 +155,173	+44%	+$26.8M	0.08%	284
2015 Q1	$60.6M	Sell	349,619 -4,323	-1%	-$782K	0.05%	426
2014 Q4	$65.5M	Sell	353,942 -6,804	-2%	-$1.26M	0.05%	378
2014 Q3	$59.8M	Buy	360,746 +1,287	+0.4%	+$211K	0.05%	404
2014 Q2	$56.2M	Buy	359,459 +4,400	+1%	+$695K	0.05%	433
2014 Q1	$54M	Sell	355,059 -46,829	-12%	-$7.45M	0.05%	434
2013 Q4	$53.5M	Sell	401,888 -10,628	-3%	-$1.28M	0.05%	420
2013 Q3	$47.9M	Sell	412,516 -23,535	-5%	-$2.58M	0.05%	441
2013 Q2	$40.2M	Buy	+436,051	New	+$42M	0.04%	451

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

AllianceBernstein's ALXN Position: Q3 2021 in Review

AllianceBernstein sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,254,045 shares — an estimated $230M sold.

AllianceBernstein first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $355M in Q3 2016. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

AllianceBernstein reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
AllianceBernstein sold 1,254,045 Alexion Pharmaceuticals shares in Q3 2021, an estimated $230M.
AllianceBernstein first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
AllianceBernstein's Alexion Pharmaceuticals position peaked at $355M in Q3 2016.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on AllianceBernstein's 13F filing for Q3 2021, filed 10 Nov 2021.